KAZIMI A J 4

What Happened

• A.J. Kazimi, reported as a 10% owner of Cumberland Pharmaceuticals (CPIX), acquired a derivative award of 100,000 shares on 2026-03-18. The reported acquisition price is $2.80 per share, for a total reported value of $280,000.
• This filing shows an acquisition/award (transaction code A), which is an insider purchase-like event rather than a sale.

Key Details

• Transaction date: 2026-03-18; Filing date: 2026-03-20 (filed within the typical 2-business-day Form 4 window).
• Shares/derivatives acquired: 100,000; Price per share: $2.80; Total reported value: $280,000.
• Transaction type: Derivative award/grant (Form 4 lists this as a derivative acquisition).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• No footnotes, 10b5-1 plan, tax withholding, or immediate sale (cashless exercise) were indicated in the supplied details.

Context

• "Derivative" awards can include stock options, restricted stock units (RSUs), or similar instruments; the Form 4 records acquisition of derivative securities but does not always specify the exact instrument without full filing text.
• As a 10% owner, Kazimi is a significant shareholder under Section 16 reporting rules; this is insider activity but not necessarily an executive's routine compensation disclosure.
• The transaction was filed promptly, so there’s no late-filing flag to note.